NCT01149421 trial results

Inclusion Criteria: * Type 2 diabetes taking 1 or more oral diabetes medications and have taken these medications for at least 1 month prior to screening * Glycosylated hemoglobin (HbA1c) value ≥7% and ≤9.5% at screening * Mean blood pressure \>90/60 millimeters of mercury (mmHg) and \<140/90 mmHg at screening * If treated for hypertension, are taking 3 or less antihypertensive medications and have been taking these medications for at least 1 month prior to screening * Stable weight for 3 months prior to screening * Body mass index (BMI) greater than or equal to 23 kilogram-meter squared (kg/m\^2) * Willing to wear an ambulatory blood pressure monitoring device for at least 24 hours on multiple occasions * Women of childbearing potential must test negative for pregnancy and be willing to use a reliable method of birth control * Male participants must use a reliable method of birth control Exclusion Criteria: * Myocardial infarction, stroke, or hospitalization for heart failure within 3 months prior to screening, or heart failure Class III or IV at screening * Ongoing or history of frequent intermittent tachyarrhythmia * Resting heart rate \<60 beats per minute (bpm) or \>100 bpm at screening * Work rotating shifts or work during the hours of 2200 to 0700 * Chronic insulin therapy * Use of a glucagon-like peptide 1 (GLP-1) receptor agonist within 3 months prior to screening, or a dipeptidylpeptidase-IV (DPP-IV) inhibitor within 2 weeks prior to screening * Nondominant arm circumference \>42 centimeter (cm) * Use of drugs to promote weight loss * Chronic use of systemic steroids * Gastric emptying abnormality or bariatric surgery * Hepatitis, other liver disease, or alanine transaminase (ALT) \>3 times the upper limit of normal * Acute or chronic pancreatitis * Severe renal impairment * Active autoimmune disease or uncontrolled endocrine abnormality * Self or family history of thyroid cancer, medullary C-cell hyperplasia, or type 2A or 2B multiple endocrine neoplasia * Calcitonin value greater than or equal to 20 picograms per milliliter (pg/ml) at screening * Transplanted organ except corneal transplants * Active or untreated cancer or in remission \<5 years, except skin, in situ cervical, or prostate cancer * Sickle-cell disease, hemolytic anemia, or another hematological condition that may interfere with HbA1c testing